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Abstract
Background: The molecular mechanisms underlying melanoma tumor development and
progression are still not completely understood. One of the new candidates that emerged from a
recent gene expression profiling study is fatty acid-binding protein 7 (FABP7), involved in lipid
metabolism, gene regulation, cell growth and differentiation.
Methods: We studied the functional role of FABP7 in human melanoma cell lines and using
immunohistochemistry analyzed its expression pattern and clinical role in 11 nevi, 149 primary
melanomas and 68 metastases.
Results: FABP7 mRNA and protein level is down-regulated following treatment of melanoma cell
lines with a PKC activator (PMA) or MEK1 inhibitor (PD98059). Down-regulation of FABP7 using
siRNA decreased cell proliferation and invasion but did not affect apoptosis. In clinical specimens,
FABP7 was expressed in 91% of nevi, 71% of primary melanomas and 70% of metastases, with a
cytoplasmic and/or nuclear localization. FABP7 expression was associated with tumor thickness in
superficial spreading melanoma (P = 0.021). In addition, we observed a trend for an association
between FABP7 expression and Ki-67 score (P = 0.070) and shorter relapse-free survival (P =
0.069) in this group of patients.
Conclusion: Our data suggest that FABP7 can be regulated by PKC and the MAPK/ERK1/2
pathway through independent mechanisms in melanoma cell lines. Furthermore, FABP7 is involved
in cell proliferation and invasion in vitro, and may be associated with tumor progression in
melanoma.
Background
Malignant melanoma is the most lethal skin cancer and
accounts for about 75% of all deaths from skin tumors. In
its early stage, melanomas can be treated surgically, but
once the tumor has progressed, it is difficult to treat and it
does not respond to current therapies. The molecular
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progression are still not completely understood, and
novel diagnostic and prognostic markers, as well as thera-
peutic targets are needed [1].
We have previously reported that phorbol-12-myristate-
13-acetate (PMA), a protein kinase C (PKC) activator,
increases proliferation and promotes anchorage-inde-
pendent survival of melanoma cells cultivated as multicel-
lular aggregates in suspension (spheroids). This protective
action was at least partly mediated through PKC and MEK-
independent activation of the mitogen-activated protein
kinase/extracellular signal-regulated kinases 1/2 (MAPK/
ERK1/2) [2]. In an attempt to identify additional genes
involved in survival and apoptosis of melanoma cells, we
used high throughput gene expression profiling (Affyme-
trix™) to identify differentially expressed genes in
untreated cells cultured as monolayer or spheroids, as
well as in spheroids treated with PMA and/or the MEK1
inhibitor PD98059. The analysis revealed that the fatty
acid-binding protein 7 (FABP7, BLBP or B-FABP) [3,4] was
among the most significantly differentially expressed
genes (unpublished results).
FABP7 belongs to a family of structurally-related proteins
showing tissue-specific patterns of expression. Nine
FABPs (FABP1 – FABP9), expressed in normal liver, intes-
tine, heart, adipose tissue, epidermis, brain, peripheral
nervous system and testis have been identified (reviewed
in [5]). FABP proteins are involved in lipid metabolism,
including uptake and intracellular trafficking of fatty acids
and retinoids. In addition, they play a role in gene regula-
tion, cell signaling, cell growth and differentiation [6].
Several reports have suggested a possible role for the dif-
ferent FABP proteins in cancer biology, linking their levels
with either increasing or decreasing degree of malignancy.
Adamson et al. reported that FABP5 (C-FABP/E-FABP)
protein expression is higher in prostate cancer compared
to prostatic hyperplasia [7]. On the other hand, the FABP1
level decreases with progression of colon cancer [8].
FABP7 is highly expressed in glia cells throughout devel-
opment of the nervous system [4,9] and high FABP7
expression in glioblastomas is related to poor prognosis
[10]. Recently, two studies have addressed FABP7 expres-
sion in surgical specimens from melanoma patients.
While de Wit et al. reported down-regulation of FABP7 in
melanomas compared to nevi, Goto et al. found FABP7 to
be frequently expressed in melanomas, and suggested that
it may play a role in cell proliferation and inva-
sion[11,12].
In the current study we examined the role of FABP7 in
proliferation, apoptosis and invasion of melanoma cells
grown in vitro and studied possible regulation mecha-
nisms of this protein. In addition, we examined the
expression of FABP7 protein in clinical melanoma speci-
mens and assessed the relationship between FABP7
expression pattern and known prognostic variables, cell
cycle factors and disease progression. We report that
FABP7 is regulated via PKC and the MAPK/ERK1/2 signal-
ing pathway in melanoma cells in vitro and promotes pro-
liferation and invasion. Moreover, FABP7 expression is
associated with tumor thickness and proliferation in
melanoma biopsies.
Methods
Cell lines and Growth Conditions
The Wistar Melanoma (WM) cell lines were kindly pro-
vided by Dr. Meenhard Herlyn (Wistar Institute, Philadel-
phia, PA) and have been described in detail elsewhere
[13].
The MeWo cell line was derived from a lymph node
metastasis [14]. The cell lines FEMX-I and LOX were estab-
lished from metastatic lymph node biopsies obtained
from melanoma patients treated at the Rikshospitalet-
Radiumhospitalet Medical Center [15]. The cells were rou-
tinely cultured in RPMI 1640 medium (BioWhittaker
Europe, Verviers, Belgium) supplemented with 5% fetal
calf serum (FCS) (Biochrom, KG, Berlin, Germany). Phor-
bol-12-myristate-13-acetate (PMA) was from Sigma-
Aldrich (St. Louis, MO), whereas the MEK1 inhibitor,
PD98059, was from Cell Signaling Technology (Beverly,
MA). Multi-cellular aggregates (spheroids) were prepared
as previously described [16]. Briefly, 24-well plates were
coated with 1% Seaplaque agarose (BioWhittaker Molec-
ular Application, Rockland, ME) and tumor cells (2 × 105
cells in 1 ml complete medium) were plated on top of the
solidified agarose. For thymidine incorporation assay,
5000 cells per well were plated in 96-well polyhema
(Sigma-Aldrich)-coated U-bottom plates. For treatment of
spheroid cultures, PMA was added when plating in sus-
pension, whereas the inhibitors in combination experi-
ments were added 45 min prior to plating as spheroids.
Gene expression analysis
WM35 cells were grown as spheroids for 24 hrs in the
presence of PMA and PD98059, alone and in combina-
tion. Total RNA was extracted using the TRIZOL reagent
(Invitrogen, Carlsbad, CA). Gene expression profiling was
performed using Affymetrix U133 Plus 2.0 arrays (Affyme-
trix, Santa Clara, CA). For microarray hybridization, the
protocol described in the Affymetrix GeneChip eukaryotic
one-cycle target preparation protocol, using 5 μg of total
RNA, was followed. Analysis of the data was performed by
Genolyze Ltd. (Turku, Finland) using statistical software R
version 2.3.0. and package collection Bioconductor ver-
sion 1.8. Statistical significance was assessed using p-valuePage 2 of 13
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with q-values to control the False Discovery Rate.
Quantitative real time RT-PCR analysis
The high capacity cDNA reverse transcription kit (Applied
Biosystems, Foster city, CA) was used to reverse-transcribe
total RNA (0.8 μg) in a 20 μl reaction mixture using ran-
dom primers. The real-time PCR analyses were performed
using TaqMan Fast Universal PCR Master Mix (2×) and
TaqMan Gene Expression Assay (HS00361426-ml FABP7,
HS99999908-ml GUS, Applied Biosystems). A total of 0.5
μl cDNA was used in 25 μl PCR mixtures with 900 nM of
each primer and 250 nM TaqMan probe. The reactions
were carried out in a 7900 HT Fast Real Time PCR system
(Applied Biosystems) with the following program: 95°C
for 20 sec. followed by 40 cycles of 95°C for 1 sec., 60°C
for 20 sec. Each sample was run in triplicate. The FABP7
relative mRNA expression level was normalized with
respect to the beta-glucuronidase (GUS) gene, which had
stable transcript levels under these experimental condi-
tions. The mean from three independent experiments was
calculated.
Immunoblotting
Cells were lysed in ice-cold NP-40 lysis buffer (1% NP-40,
10% glycerol, 20 mM Tris-HCl, pH 7.5, 137 mM NaCl,
100 mM sodium vanadate, 1 mM phenylmethylsulfonyl
fluoride (PMSF), 0.02 mg/ml each of aprotinin, leupep-
tin, and pepstatin, and 10 μl/ml phosphatase inhibitor
cocktail I and II (Sigma-Aldrich)). Protein quantitation
was done by Bradford analysis and 25 μg protein/lane was
resolved by SDS polyacrylamide gel electrophoresis.
Transfer and hybridization were as described in [17]. To
ensure even loading, filters were stained with naphthol-
blue black (Sigma-Aldrich) and re-stained with α-tubulin.
The antibodies against FABP7 and α-tubulin were from
R&D Systems (Minneapolis, MN) and Calbiochem (San
Diego, CA), respectively. HRP-conjugated anti-mouse IgG
secondary antibody was from Promega (Madison, WI)
and HRP-conjugated anti-goat secondary antibody was
from DAKO A/S (Glostrup, Denmark).
Small interfering RNA transfection
Fifty thousand cells per well were seeded in 24-well plates
for 24 hrs prior to transfection with 50 nM siRNA target-
ing FABP7 (OligioID: HSS103516; Catalog# 1299003) or
negative control siRNA duplexes (Catalog#12935-300)
using Lipofectamine™ RNAiMAX transfection reagent (all
reagents and siRNA were from Invitrogen). Cells were
detached 48 hours after transfection and plated into agar-
ose-coated 24-well plates as spheroids for an additional
72 hrs for assessment of apoptosis, seeded into 96-well
polyhema-coated U-bottom plates for the proliferation
assay and plated in BioCoat Matrigel invasion chambers.
Proliferation assay
Five thousand cells per well were seeded in 96-well poly-
hema-coated U-bottom plates for spheroids and in 96-
well flat-bottom plates for monolayer cells and cultured
for 72 hrs, the last 24 hrs with the addition of 3.7 × 104 Bq
[3H]Thymidine (ARC, St.Louis, MO) Thereafter, the cells
were harvested using a Filtermate Harvester (Packard
Instrument Co. Meriden, CT). [3H]Thymidine incorpora-
tion was assessed in a Packard Microplate Scintillation
Counter. Proliferation assays were measured in triplicate.
The experiment was repeated at least three times.
Flow cytometric analysis of apoptosis
The adherent cells were harvested by Trypsin and together
with detached cells fixated in 100% cold methanol. Fixed
cells were washed with PBS, incubated for 30 min at 37°C
in 50 μl terminal transferase (TdT) solution containing 5
units TdT (Roche, Basel, Switzerland), 10 μl 5× reaction
buffer (supplied with TdT), 1.5 mM CoCl2, 0.5 nmol
labeled biotin-16-dUTP, 0.1 mM dithiothreitol and dis-
tilled water. The cells were subsequently washed once in
PBS containing 0.1% Triton X-100 and incubated in 50 μl
1:50 streptavidin-FITC (Amersham, Buckinghamshire,
UK) in PBS (0.1% Triton X-100) and 3% skimmed dry
milk for 45 min at room temperature. After washing in
PBS (0.1% Triton X-100) the pellet was resuspended in
PBS (0.1% Triton X-100) containing 2 μg/ml Hoechst
33258 to a final concentration of 1 × 106 cells/ml and
incubated for 30 min at 4°C. Data acquisition and analy-
sis were performed on Becton Dickinson LARII (Becton
Dickinson immunocytometry systems, San Jose, CA)
using Multifit software (FACSDiVa House inc., Tonsham,
ME).
Matrigel invasion assay
WM35 and WM239 cells were plated in BioCoat Matrigel
invasion chambers (BD Biosciences, San Jose, CA) at a cell
density of 3 × 104 per chamber in RPMI 1640 supple-
mented with 5% fetal bovine serum (inner chamber) 48
hrs post-transfection. Self-supplied fibroblast conditioned
medium was used as chemoattractant in the outer cham-
ber. The conditioned medium was obtained from fibrob-
lasts isolated as described by Costea et al[18] cultivated in
DMEM supplemented with 10% fetal bovine serum. The
medium was collected when the cells were 70% confluent.
After 48 hrs incubation at 37°C and 5% CO2, non-invad-
ing cells remaining on the top surface of the chamber were
removed by scrubbing with a cotton-tipped swab, and the
invading cells that had adhered to the bottom surface of
the chamber membranes were fixed, stained with hema-
toxylin and counted.
Clinical melanoma specimens
Formalin-fixed, paraffin-embedded tissue from 149 pri-
mary and 68 metastatic melanomas, as well as 11 benignPage 3 of 13
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the primary tumors, 93 were classified as superficial
spreading (SSM) and 56 as nodular melanomas (NM).
Clinical follow-up was available for all patients. The study
was approved by the Regional Committee for Medical
Research Ethics in Norway.
Immunohistochemical analysis
Sections of formalin-fixed, paraffin-embedded tissue were
immunostained using the two-step EnVision system
(DAKO EnVision™, DAKO A/S). Deparafinized sections
were microwaved in low pH buffer (pH 6.0) (DAKO) at
750 W for 5 minutes and then at 500 W for 15 minutes to
unmask the epitopes. After treatment with 1% hydrogen
peroxide for 5 minutes to block endogenous peroxidase,
the sections were incubated with polyclonal rabbit anti-
human FABP7 antibody (R&D Systems) for 30 minutes at
room temperature followed by 30 minutes incubation
with mouse anti-goat antibody (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA). The sections were then incubated
with HRP-labeled secondary antibody for 30 minutes fol-
lowed by 5 minutes incubation at RT with DAB substrate
(DAKO A/S). All series included positive controls. Four
semiquantitative classes were used to describe the number
of stained cells: negative, ≤ 5%, 6–50% and >50%. Both
nuclear and cytoplasmic staining was scored. Staining was
evaluated by a surgical pathologist (BD). A subset of the
cases (n = 50) was additionally scored by another author
(AS).
Statistical analysis
Statistical analysis was performed using the SPSS program
version 13.0 (Chicago, IL). The differences between
FABP7 expression in benign nevi, primary melanomas
and metastases were analyzed using the Chi-square test.
The relationship between FABP7 expression and mean
tumor thickness was evaluated nonparametrically using
the Mann-Whitney two sample test. The association
between expression of FABP7 and cell cycle markers was
performed using the Fischer's exact test. Kaplan-Meyer
estimates and the log-rank test were used for survival anal-
ysis. P < 0.05 was considered statistically significant.
Results
Identification of molecules involved in survival of 
melanoma cells as multicellular aggregates in suspension 
using gene expression profiling
We previously showed that PMA treatment protects
melanoma cells from suspension-mediated apoptosis
while the MEK1 inhibitor PD98059 has the opposite
effect [2]. In order to identify new factors involved in
anchorage-independent growth of melanoma cells, we
compared mRNA expression profiles from the melanoma
cell line WM35, cultured in monolayer or as untreated
spheroids, as well as following treatment of the spheroids
with PMA and/or PD98059 for 24 hours.
The FABP7 gene was among the genes showing the highest
differential expression. While no notable difference was
observed between monolayer cells and spheroids, treat-
ment with PMA or PD98059, as well as with PD98059
and PMA in combination, led to FABP7 mRNA down-reg-
ulation in treated spheroids compared to the spheroid
control (Figure 1a). The microarray results were validated
using real time RT-PCR (Figure 1b).
FABP7 is expressed in melanoma cell lines and regulated 
through PKC and the MAPK/ERK1/2 signaling pathway
The protein level of FABP7 in monolayer culture,
untreated spheroids and spheroids treated with PMA and/
or PD98059 for 24 hrs was analyzed using western blot.
As shown in Figure 1c, no change in FABP7 protein level
was observed between monolayer cells and untreated
spheroids while in spheroids treated with PMA and/or
PD98059, the protein level was reduced compared to con-
trols. This was in accordance with the reduction of FABP7
mRNA levels. A similar reduction in FABP7 protein level
was obtained in monolayer cultures treated with PMA
and/or PD98059 (data not shown).
In order to reveal if FABP7 expression levels differ during
the cultivation of the WM35 cells following PMA and/or
PD98059 treatment, we performed a time course study.
The monolayer cells were treated with PMA or PD98059
from 0,5 hrs to 72 hrs. As shown in Figure 2. we observed
down-regulation of FABP7 protein after 12 hrs in both
PMA and PD98059 treated cells although the effect of
PMA was more pronounced over time. The down-regula-
tion was sustained for up to 72 hrs for both treatments.
These results were supported by real time RT-PCR (data
not shown).
To examine if FABP7 is frequently expressed in melanoma
cell lines we analyzed the level of FABP7 mRNA and pro-
tein in two primary (WM1341 and WM902B) and seven
metastatic cell lines (WM239, WM45.1, WM983, WM9,
LOX, MeWo and FEMX-I) in addition to WM35. As shown
in Figure 3a and 3b, variable levels of FABP7 mRNA and
protein were detected in 9 out of 10 cell lines. With the
exception of WM45.1, good concordance between mRNA
and protein levels was observed in all the cell lines. No
clear differences were observed between FABP7 expression
levels in cell lines originating from primary tumor vs.
metastasis.
FABP7 is involved in proliferation and invasion of 
melanoma cells
In order to further investigate the function of FABP7 we
chose to transiently down-regulate FABP7 using specificPage 4 of 13
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A) The expression level of FABP7 as detected by Affymetrix microarray analysis in WM35 cells grown as spheroids for 24 hrs with or without PMA and/or PD98059 compared to untreated m nol er controlFigur 1
A) The expression level of FABP7 as detected by Affymetrix microarray analysis in WM35 cells grown as sphe-
roids for 24 hrs with or without PMA and/or PD98059 compared to untreated monolayer control. B) FABP7 
mRNA expression levels in the same cells as in (A) measured by real time RT-PCR. The results presented are relative to 
untreated monolayer control. The average was calculated from three independent experiments and presented with standard 
deviation. C) Expression of the FABP7 protein by Western blot analysis. Down-regulation of FABP7 mRNA and protein was 
seen after treatment with PMA and PD98059 for 24 hrs. α-tubulin was used as loading control.
BMC Cancer 2008, 8:276 http://www.biomedcentral.com/1471-2407/8/276siRNA in the WM35 and WM239 cell lines, which we
found to have high FABP7 expression. The effect of down-
regulation on proliferation, invasion and apoptosis was
examined. Monolayer cells were incubated for 48 hrs with
FABP7 siRNA or a control siRNA and analyzed for trans-
fection efficiency by western blot (Figure 4a). As demon-
strated in figure 4b and 4c, FABP7 down-regulation
reduced proliferation by 29% in WM35 and 84% in
WM239 cells as compared to scrambled siRNA control
transfected cells. Similar results were obtained when the
cells were grown in suspension (data not shown).
The degree of apoptosis was assessed using TdT-mediated
dUTP nick end labeling (TUNEL) staining and flow
cytometry. Analysis of both monolayer and spheroid cul-
tures showed that down-regulation of FABP7 did not
affect the percentage of apoptotic cells (data not shown).
Together these results suggest that FABP7 is most likely
involved in proliferation and not apoptosis in melanoma
cells.
We investigated the effect of FABP7 down-regulation on
invasion using the Matrigel assay. The number of invading
cells was reduced by 55% and 40% in WM35 and WM239
cell respectively after transfection with FABP7 siRNA com-
pared with scrambled siRNA control-transfected cells (Fig-
ure 4d), suggesting that FABP7 contributes to the
invasiveness of melanoma cells.
FABP7 is expressed in melanomas and associated with 
tumor thickness
In order to examine the clinical relevance of FABP7, paraf-
fin-embedded tissue from a panel of benign nevi and pri-
mary and metastatic melanomas was analyzed for
expression of FABP7 protein using immunohistochemis-
try. Heterogeneous cytoplasmic and/or nuclear expression
of FABP7 was observed in 91% of the nevi, 71% of the pri-
mary tumors and 70% of the metastases. The results are
summarized in Table 1 and 2 and illustrated in Figure 5.
Statistical analysis demonstrated a significant higher cyto-
plasmic FABP7 expression in nevi compared to primary
and metastatic melanomas (P = 0.023), with comparable
nuclear expression. A two-tier analysis of primary and
metastatic melanomas showed comparable expression for
both cytoplasmic and nuclear expression (P > 0.05). Good
concordance (>80%) was achieved between the two
observers. Discrepant cases were resolved through a con-
sensus session.
Since 62% (92/149) of the primary tumors expressed
cytoplasmic FABP7 in more than 5% of the cells, this cut-
off was used to distinguish between high and low protein
levels. Applying the same cutoff when evaluating nuclear
staining, we observed that only 13% (19/149) of the
tumors had high protein expression levels. Higher cyto-
plasmic FABP7 was significantly associated with increased
thickness of SSM (P = 0.021). In addition, in this group of
patients, a trend towards increased relapse-free survival (P
= 0.069) for patients whose tumors expressed less FABP7
was observed. No such correlation was observed in NM
(Table 3 and Figure 6). We did not observe any significant
correlation between FABP7 staining and overall survival
for patients diagnosed with either SSM or NM (data not
shown). Nuclear staining had no association with disease
outcome (data not shown).
Relationship between FABP7 expression and markers of 
proliferation
Since our panel of primary and metastatic melanomas has
previously been analyzed for expression of cell cycle pro-
gression markers [19-21] and activation status of MAPK/
ERK1/2 [22], it was of interest to examine the relationship
between FABP7 expression and the levels of these factors.
The results showed no correlation between cytoplasmic
FABP7 expression and the expression of the cyclins A, D1
or D3 or the cdk inhibitors p21CIP1/WAF1and p27Kip1 in
either SSM or NM. However, a trend for an association
between cytoplasmic FABP7 and Ki-67 (P= 0.07) in SSM
was observed, which is in support of our in vitro results,
suggesting FABP7 involvement in proliferation. Further-
more, expression of activated MAPK/ERK1/2 did not cor-
Western blot showing the expression of the FABP7 protein in WM35 monolayer cells treated with PMA or PD98059 for 0.5 hrs, 4 hrs, 12 hrs, 24 hrs, 48 hrs and 72 hrsFigu e 2
Western blot showing the expression of the FABP7 
protein in WM35 monolayer cells treated with PMA 
or PD98059 for 0.5 hrs, 4 hrs, 12 hrs, 24 hrs, 48 hrs 
and 72 hrs. α-tubulin was used as loading control.Page 6 of 13
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observed that if the cutoff level was changed (only total
lack of FABP7 was regarded as low expression), MAPK/
ERK1/2 expression did positively correlate with cytoplas-
mic FABP7 expression in SSM (P= 0.047). This was not the
case for NM, regardless of cutoff. Nuclear expression of
FABP7 did not correlate with any of the examined markers
(data not shown).
A) FABP7 mRNA level in melanoma cell lines as measured by real time RT-PCR analysisFigure 3
A) FABP7 mRNA level in melanoma cell lines as measured by real time RT-PCR analysis. Three primary and 7 
metastatic melanoma cell lines were evaluated. The expression levels are shown relative to the WM35 cell line. B) Expression 
of FABP7 protein by western blotting, with α-tubulin as loading control.Page 7 of 13
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A) Western blot analysis showing down-regulation of FABP7 in WM35 and WM239 cells after transfection with FABP7 siRNA, with α-tubulin as lo ding controlFigur  4
A) Western blot analysis showing down-regulation of FABP7 in WM35 and WM239 cells after transfection 
with FABP7 siRNA, with α-tubulin as loading control.B-C) The effect of FABP7 down-regulation on proliferation in 
WM35 (B)and WM239 (C)cells measured by [3H]Thymidine incorporation 72 hrs post transfection. Down-regulation of 
FABP7 protein using siRNA led to reduction of DNA synthesis, suggesting reduced proliferation in both cell lines.D) Matrigel 
invasion assay. Inhibition of invasion ability of WM35 and WM239 cells following FABP7 down-regulation with siRNA. The 
average was calculated from three independent experiments and presented with standard deviation.
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We previously showed that PMA-mediated PKC activation
and activation of the MAPK/ERK1/2 pathway contributes
to increased proliferation and reduced apoptosis of
melanoma cells under anchorage-deprived conditions. In
the present study we used gene expression profiling to
identify additional genes involved in these processes, and
found the FABP7 gene to be differentially expressed and
down-regulated in WM35 spheroids following both PKC
activation and MEK1 inhibition while no differences were
observed between monolayer cells and untreated sphe-
roids. PKC activation and MAPK/ERK1/2 down-regula-
tion had opposite effect on anchorage-independent
survival of the melanoma cells, but both negatively regu-
lated FABP7. This observation argues against FABP7
involvement in promotion of anchorage-independent
survival in these cells. Thus, it is likely that these pathways
are regulating additional factors important for survival,
independent of FABP7 down-regulation.
PKC is a well known activator of the MAPK/ERK1/2 path-
way [23,24] and we have previously reported that PMA
activates MAPK/ERK1/2 independently of its upstream
activator MEK1 [2]. Since PMA treatment down-regulates
FABP7 even in the presence of activated ERK1/2 this
down-regulation is likely to be PMA/PKC-mediated but
MAPK/ERK1/2-independent. Together this suggests that
FABP7 can be regulated by both signaling pathways inde-
pendently in melanoma cells. Several reports have shown
that activation of the MAPK/ERK1/2 pathway can induce
increased activity of peroxisome proliferator-activated
receptors α/γ (PPAR α/γ). Similarly, PKC can both posi-
tively and negatively regulate PPARα-dependent tran-
scription [25-27]. Binding of PPARγ to its response
element, PPRE, has been shown to up-regulate FABP1 and
FABP4 [5,28,29]. It is reasonable, therefore, to assume
that FABP7 might also be regulated through this mecha-
nism.
To further clarify the role of FABP7 in melanomas we used
siRNA to down-regulate its expression in the primary
WM35 and metastatic WM239 melanoma cell lines. This
down-regulation notably inhibited proliferation in both
cell lines, but did not affect the degree of apoptosis, argu-
ing for involvement of FABP7 in melanoma proliferation.
In support of our results, Goto et al [12] showed that pro-
liferation of melanoma cell lines is reduced upon down-
regulation of FABP7, also without affecting apoptosis.
Our results showed that down-regulation of FABP7 nega-
tively influences the invasive potential of melanoma cells,
also in agreement with Goto et al [12] who demonstrated
that down-regulation of FABP7 decreased invasiveness in
2 of 6 melanoma cell lines. In further support of this
hypothesis are the data of Mita et al., who showed that
FABP7 increases the invasion properties of astrocytoma
cells [30]. Of note, when FABP7 was reintroduced in the
metastatic cell line LOX, lacking constitutive FABP7
expression, no effect on apoptosis, proliferation or inva-
sion was observed (preliminary results, data not shown).
Similar results were reported by Goto et al. [12] in 4 out of
6 melanoma cell lines. However, the reason for the dis-
crepancy between the cell lines is still unclear. Thus, the
biological role and detailed functional mechanism of the
FABP7 protein in melanoma cells remains to be further
investigated.
Table 2: Number (percentage) of melanocytic lesions expressing different levels of FABP7
Tumor type No. of tumors Cytoplasm Nucleus
- ≤ 5% 6–50% > 50% - ≤ 5% 6–50% > 50%
Benign nevi 11 1 (9) 0 (-) 1 (9) 9 (82) 3 (28) 4 (36) 4 (36) 0 (-)
Primary melanomas 149 43 (28) 14 (9) 42 (28) 50 (34) 79 (53) 51 (34) 16 (11) 3 (2)
SSM 93 32 (34) 10 (11) 25 (27) 26 (28) 51 (55) 31 (33) 9 (10) 2 (2)
NM 56 11 (20) 4 (7) 17 (30) 24 (43) 28 (50) 20 (36) 7 (12) 1 (2)
Metastases 68 21 (31) 8 (11) 21 (31) 18 (27) 40 (59) 20 (29) 7 (11) 1 (1)
Table 1: Number (percentage) of melanocytic lesions expressing FABP7 in different cellular compartments
Tumor Type No. of tumors Total no. of positive Cytoplasm Nucleus Cytoplasm/nucleus
Benign nevi 11 10 (91) 2 (18) 0 (0) 8 (73)
Primary melanomas 149 106 (71) 36 (24) 0 (0) 70 (47)
SSM 93 61 (66) 19 (21) 0 (0) 42 (45)
NM 56 45 (80) 17 (30) 0 (0) 28 (50)
Metastases 68 48 (70) 20 (29) 1 (2) 27 (39)Page 9 of 13
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Immunohistochemical staining of FABP7 in a benign nevus (A) primary melanoma (B) and metastatic melanoma (C)Figure 5
Immunohistochemical staining of FABP7 in a benign nevus (A) primary melanoma (B) and metastatic 
melanoma (C).
BMC Cancer 2008, 8:276 http://www.biomedcentral.com/1471-2407/8/276Several members of the FABP family have been reported
to be differentially expressed in cancer. Loss of expression
of FABP4 was reported in bladder cancer while FABP1 and
FABP2 are over-expressed in prostate and breast cancers
[7,31-33]. In accordance with Goto et al. [12] we found
that FABP7 is expressed in both primary and metastatic
melanoma cell lines, as well as in melanocytic lesions.
However, there were no clear differences in FABP7 expres-
sion levels in primary derived compared to metastatic
derived cell lines, suggesting that FABP7 is not associated
with tumor aggressiveness. On the other side, cell lines are
cultured in artificial environments that can not be directly
compared to tumors in vivo and a connection to tumor
aggressiveness and progression can not be completely
excluded. In support of this, analysis of the clinical data
showed that thicker SSM expressed higher levels of FABP7.
Furthermore, a trend between high levels of FABP7 and
reduced disease-free survival for these patients suggest
that FABP7 could contribute to disease progression, possi-
bly by increasing the invasion potential of the tumors. In
support of our results, a negative association between
FABP7 expression and survival was recently observed for
patients with glioblastoma [10,34]. We also observed a
positive trend between FABP7 and the proliferation
Table 3: Relationship between cytoplasmic FABP7 expression and tumor thickness in primary melanomas
Tumor type Expression No of patients Average depth of growth (mm) P
SSM Negative* 41 1.59
Positive 48 2.17 0.021
NM Negative* 15 4.32
Positive 41 4.78 0.697
* Considered negative if < 5% tumor cells showed positive immunoreactivety of FABP7
Kaplan-Meier curve demonstrating a negative trend (P = 0.069) between protein expression of cytoplasmic FABP7 and relapse-free survival for patients with SSMFigure 6
Kaplan-Meier curve demonstrating a negative trend (P = 0.069) between protein expression of cytoplasmic 
FABP7 and relapse-free survival for patients with SSM. FABP7 expression was considered high when > 5% of the 
tumor cells showed positive staining with the anti-FABP7 antibody.Page 11 of 13
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BMC Cancer 2008, 8:276 http://www.biomedcentral.com/1471-2407/8/276marker Ki-67 in SSM, suggesting that FABP7 may contrib-
ute to increased proliferation in vivo. Since the patient sub-
groups in the analyses were small, the suggested clinical
significance of FABP7 expression remains to be confirmed
in larger patient cohorts.
In the clinical specimens, FABP7 protein expression was
highest in nevi, with no observed differences between pri-
mary and metastatic melanoma. This is in accordance
with the study by de Wit et al. [11] who reported that
FABP7 is down-regulated in melanoma tissue compared
to nevi using oligonucleotide arrays. The higher expres-
sion of FABP7 in nevi compared to melanomas seems
contradictory to the in vitro data in the present study, as
well as to the association with clinical parameters of dis-
ease progression. We are unable to explain this discrep-
ancy at present. However, the majority of benign nevi are
terminal lesions that do not progress to melanoma and
the molecular events regulating these processes might dif-
fer. It is also possible that different expression levels of
FABP7 mediate different effects during disease progres-
sion.
Variation in sub-cellular localization of FABP7 has been
reported in developing radial glia cells, glioma cell lines
[9,35] and glioblastoma multiforme (GBM) specimens
[34]. Since FABP proteins are considered to be co-activa-
tors in PPAR-mediated gene transcription control, this
could in part explain FABP7 translocation to the nucleus
(reviewed in [5]). Recently, it was reported that nuclear
expression of FABP7 is restricted to infiltrative tumor
types and related to EGFR amplification and over-expres-
sion as well as poor prognosis of GBM [10,34]. In our
melanoma cohort we did not find any association
between nuclear expression of FABP7 and disease-free or
overall survival.
Conclusion
We confirmed that FABP7 protein is expressed in melano-
cytic lesions and showed that it can regulate proliferation
and invasion in melanoma cells in vitro. Our results fur-
ther suggest that FABP7 can be regulated by PKC and the
MAPK/ERK1/2 pathway through independent mecha-
nisms. In addition, FABP7 expression is associated with
proliferation and tumor thickness in the patients with
SSM, suggesting that for these patients FABP7 could be a
potential target for therapy.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
AS carried out the siRNA transfections, invasion experi-
ments and evaluated immunohistochemical staining and
drafted the manuscript. KJ performed immunohistochem-
istry, flow cytometry, and contributed to drafting the
manuscript. MS and AKRR carried out optimalization of
the real-time PCR and antibodies used in western blotting
in the study. MS also performed technical phase of micro-
array experiment. BD evaluated immunohistochemical
staining. GT participated in the design of the study and
microarray analysis. VAF conceived of the study, and par-
ticipated in its design and coordination and helped to
draft the manuscript. All authors read and approved the
final manuscript.
Acknowledgements
This work was supported by The Norwegian Cancer Society
References
1. Miller AJ, Mihm MC Jr: Melanoma.  N Engl J Med 2006, 355:51-65.
2. Jorgensen K, Skrede M, Cruciani V, Mikalsen SO, Slipicevic A,
Florenes VA: Phorbol ester phorbol-12-myristate-13-acetate
promotes anchorage-independent growth and survival of
melanomas through MEK-independent activation of ERK1/2.
Biochem Biophys Res Commun 2005, 329:266-274.
3. Schnutgen F, Borchers T, Muller T, Spener F: Heterologous
expression and characterisation of mouse brain fatty acid
binding protein.  Biol Chem Hoppe Seyler 1996, 377:211-215.
4. Shimizu F, Watanabe TK, Shinomiya H, Nakamura Y, Fujiwara T: Iso-
lation and expression of a cDNA for human brain fatty acid-
binding protein (B-FABP).  Biochim Biophys Acta 1997,
1354:24-28.
5. Haunerland NH, Spener F: Fatty acid-binding proteins–insights
from genetic manipulations.  Prog Lipid Res 2004, 43:328-349.
6. Glatz JF, Storch J: Unravelling the significance of cellular fatty
acid-binding proteins.  Curr Opin Lipidol 2001, 12:267-274.
7. Adamson J, Morgan EA, Beesley C, Mei Y, Foster CS, Fujii H, Rudland
PS, Smith PH, Ke Y: High-level expression of cutaneous fatty
acid-binding protein in prostatic carcinomas and its effect on
tumorigenicity.  Oncogene 2003, 22:2739-2749.
8. Lawrie LC, Dundas SR, Curran S, Murray GI: Liver fatty acid bind-
ing protein expression in colorectal neoplasia.  Br J Cancer
2004, 90:1955-1960.
9. Feng L, Hatten ME, Heintz N: Brain lipid-binding protein (BLBP):
a novel signaling system in the developing mammalian CNS.
Neuron 1994, 12:895-908.
10. Kaloshi G, Mokhtari K, Carpentier C, Taillibert S, Lejeune J, Marie Y,
Delattre JY, Godbout R, Sanson M: FABP7 expression in glioblas-
tomas: relation to prognosis, invasion and EGFR status.  J
Neurooncol 2007, 84:245-248.
11. de Wit NJ, Rijntjes J, Diepstra JH, van Kuppevelt TH, Weidle UH,
Ruiter DJ, van Muijen GN: Analysis of differential gene expres-
sion in human melanocytic tumour lesions by custom made
oligonucleotide arrays.  Br J Cancer 2005, 92:2249-2261.
12. Goto Y, Matsuzaki Y, Kurihara S, Shimizu A, Okada T, Yamamoto K,
Murata H, Takata M, Aburatani H, Hoon DS, et al.: A new
melanoma antigen fatty acid-binding protein 7, involved in
proliferation and invasion, is a potential target for immuno-
therapy and molecular target therapy.  Cancer Res 2006,
66:4443-4449.
13. M-Yu Hau: Melanoma: The Wister Melanoma (WM) Cell
Lines.  Human Cell Culture 1998, 1:259-274.
14. Ishikawa M, Dennis JW, Man S, Kerbel RS: Isolation and character-
ization of spontaneous wheat germ agglutinin-resistant
human melanoma mutants displaying remarkably different
metastatic profiles in nude mice.  Cancer Res 1988, 48:665-670.
15. Fodstad O, Kjonniksen I, Aamdal S, Nesland JM, Boyd MR, Pihl A:
Extrapulmonary, tissue-specific metastasis formation in
nude mice injected with FEMX-I human melanoma cells.
Cancer Res 1988, 48:4382-4388.
16. Kobayashi H, Man S, Graham CH, Kapitain SJ, Teicher BA, Kerbel RS:
Acquired multicellular-mediated resistance to alkylating
agents in cancer.  Proc Natl Acad Sci USA 1993, 90:3294-3298.Page 12 of 13
(page number not for citation purposes)
BMC Cancer 2008, 8:276 http://www.biomedcentral.com/1471-2407/8/276Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
17. Dulic V, Lees E, Reed SI: Association of human cyclin E with a
periodic G1-S phase protein kinase.  Science 1992,
257:1958-1961.
18. Costea DE, Loro LL, Dimba EA, Vintermyr OK, Johannessen AC:
Crucial effects of fibroblasts and keratinocyte growth factor
on morphogenesis of reconstituted human oral epithelium.
J Invest Dermatol 2003, 121:1479-1486.
19. Florenes VA, Maelandsmo GM, Faye R, Nesland JM, Holm R: Cyclin
A expression in superficial spreading malignant melanomas
correlates with clinical outcome.  J Pathol 2001, 195:530-536.
20. Florenes VA, Faye RS, Maelandsmo GM, Nesland JM, Holm R: Levels
of cyclin D1 and D3 in malignant melanoma: deregulated
cyclin D3 expression is associated with poor clinical outcome
in superficial melanoma.  Clin Cancer Res 2000, 6:3614-3620.
21. Florenes VA, Maelandsmo GM, Kerbel RS, Slingerland JM, Nesland JM,
Holm R: Protein expression of the cell-cycle inhibitor p27Kip1
in malignant melanoma: inverse correlation with disease-
free survival.  Am J Pathol 1998, 153:305-312.
22. Jorgensen K, Holm R, Maelandsmo GM, Florenes VA: Expression of
activated extracellular signal-regulated kinases 1/2 in malig-
nant melanomas: relationship with clinical outcome.  Clin Can-
cer Res 2003, 9:5325-5331.
23. Mauro A, Ciccarelli C, De CP, Scoglio A, Bouche M, Molinaro M,
Aquino A, Zani BM: PKCalpha-mediated ERK, JNK and p38
activation regulates the myogenic program in human rhab-
domyosarcoma cells.  J Cell Sci 2002, 115:3587-3599.
24. Park MJ, Park IC, Lee HC, Woo SH, Lee JY, Hong YJ, Rhee CH, Lee
YS, Lee SH, Shim BS, et al.: Protein kinase C-alpha activation by
phorbol ester induces secretion of gelatinase B/MMP-9
through ERK 1/2 pathway in capillary endothelial cells.  Int J
Oncol 2003, 22:137-143.
25. Burns KA, Vanden Heuvel JP: Modulation of PPAR activity via
phosphorylation.  Biochim Biophys Acta 2007, 1771:952-960.
26. Blanquart C, Mansouri R, Paumelle R, Fruchart JC, Staels B, Glineur
C: The protein kinase C signaling pathway regulates a molec-
ular switch between transactivation and transrepression
activity of the peroxisome proliferator-activated receptor
alpha.  Mol Endocrinol 2004, 18:1906-1918.
27. Delmotte MH, Tahayato A, Formstecher P, Lefebvre P: Serine 157,
a retinoic acid receptor alpha residue phosphorylated by
protein kinase C in vitro, is involved in RXR. RARalpha het-
erodimerization and transcriptional activity.  J Biol Chem 1999,
274:38225-38231.
28. Issemann I, Prince R, Tugwood J, Green S: A role for fatty acids
and liver fatty acid binding protein in peroxisome prolifera-
tion?  Biochem Soc Trans 1992, 20:824-827.
29. Tontonoz P, Hu E, Graves RA, Budavari AI, Spiegelman BM: mPPAR
gamma 2: tissue-specific regulator of an adipocyte enhancer.
Genes Dev 1994, 8:1224-1234.
30. Mita R, Coles JE, Glubrecht DD, Sung R, Sun X, Godbout R: B-
FABP-expressing radial glial cells: the malignant glioma cell
of origin?  Neoplasia 2007, 9:734-744.
31. Das R, Hammamieh R, Neill R, Melhem M, Jett M: Expression pat-
tern of fatty acid-binding proteins in human normal and can-
cer prostate cells and tissues.  Clin Cancer Res 2001, 7:1706-1715.
32. Hammamieh R, Chakraborty N, Barmada M, Das R, Jett M: Expres-
sion patterns of fatty acid binding proteins in breast cancer
cells.  J Exp Ther Oncol 2005, 5:133-143.
33. Ohlsson G, Moreira JM, Gromov P, Sauter G, Celis JE: Loss of
expression of the adipocyte-type fatty acid-binding protein
(A-FABP) is associated with progression of human urothelial
carcinomas.  Mol Cell Proteomics 2005, 4:570-581.
34. Liang Y, Bollen AW, Aldape KD, Gupta N: Nuclear FABP7 immu-
noreactivity is preferentially expressed in infiltrative glioma
and is associated with poor prognosis in EGFR-overexpress-
ing glioblastoma.  BMC Cancer 2006, 6:97.
35. Godbout R, Bisgrove DA, Shkolny D, Day RS III: Correlation of B-
FABP and GFAP expression in malignant glioma.  Oncogene
1998, 16:1955-1962.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2407/8/276/pre
pubPage 13 of 13
(page number not for citation purposes)
